CoChat

Precision oncology based on omics data: The NCT Heidelberg experience

Open access
Horak, Peter, Klink, Barbara, Heining, Christoph, Gröschel, Stefan, Hutter, Barbara, Fröhlich, Martina, Uhrig, Sebastian, Hübschmann, Daniel, Schlesner, Matthias, Eils, Roland, Richter, Daniela, Pfütze, Katrin, Geörg, Christina, Meißburger, Bettina, Wolf, Stephan, Schulz, Angela, Penzel, Roland, Herpel, Esther, Kirchner, Martina, Lier, Amelie, Endris, Volker, Singer, Stephan, Schirmacher, Peter, Weichert, Wilko, Stenzinger, Albrecht, Schlenk, Richard F., Schröck, Evelin, Brors, Benedikt, von Kalle, Christof, Glimm, Hanno, Fröhling, Stefan · 2017 · International Journal of Cancer
Cited by 173

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high‐resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next‐generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology‐driven stratification of younger adults with advanced‐stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole‐exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence‐based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case‐by‐case basis toward controlled clinical trials of genomics‐guided treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.30828

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Horak, P., Klink, B., Heining, C., Gröschel, S., Hutter, B., Fröhlich, M., Uhrig, S., Hübschmann, D., Schlesner, M., Eils, R., Richter, D., Pfütze, K., Geörg, C., Meißburger, B., Wolf, S., Schulz, A., Penzel, R., Herpel, E., Kirchner, M., Lier, A., Endris, V., Singer, S., Schirmacher, P., Weichert, W., Stenzinger, A., Schlenk, R. F., Schröck, E., Brors, B., von Kalle, C., Glimm, H., & Fröhling, S.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2017-06-21
Volume
141
Issue
5
Pages
877-886
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2622985700
Cited by
173
References
13
FWCI
5.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.